Table of Contents

Report
CVM Updates
FOI Summary

Recombinant bovine somatotropin (rbST), which is also known as recombinant bovine growth hormone, is an animal drug product used to increase milk production in dairy cows. FDA approved a bovine somatotropin (rbST) product in 1993 after a comprehensive review of the product's safety and efficacy, including human food safety.

Report

Report on the Food and Drug Administration's Review of the Safety of Recombinant Bovine Somatotropin - Feb 10, 1999

CVM Updates

• FDA Responds to Citizen Petition on BST, April 21, 2000

• FDA Analysis of DGXXIV Report on Public Health Aspects of BST, April 13, 1999

• Update on Human Food Safety of BST, February 5, 1999

• Update on Bovine Somatotropin, January 14, 1999

• VMAC Endorses Post-Approval Monitoring Program for Posilac , December 18, 1996

• FDA Veterinary Medicine Advisory Committee to Meet, October 31, 1996

• Two Year Report on BST, May 16, 1996

• BST Update, March 21, 1996

Freedom of Information Summary

• NADA 140-872 POSILAC®
  (sterile sometribove zinc suspension)

• POSILAC Finding of No Significant Impact (FONSI) and Environmental Assessment (EA) - Note: .pdf file size 4.8KB

Due to the size of the Attachment List the attachments are not included with this document. Please request them under the Freedom of Information Act. Information on how to do so can be found in the Handbook for Requesting Information and Records From FDA.

CVM A-Z Index | Contact CVM | About CVM | Site Map
FDA Home Page | Search FDA Site | FDA A-Z Index | Contact FDA | Privacy | Accessibility | HHS Home Page